Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Share-based Compensation (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Share-based Compensation for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 51.09% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, down 46.09% year-over-year, with the annual reading at $6.8 million for FY2025, 46.09% down from the prior year.
  • Share-based Compensation for Q4 2025 was $1.3 million at Century Therapeutics, up from $891000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $4.0 million in Q3 2023, with the low at -$7.9 million in Q4 2022.
  • Average Share-based Compensation over 4 years is $2.1 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 144.94% in 2023, then crashed 73.15% in 2025.
  • Over 4 years, Share-based Compensation stood at -$7.9 million in 2022, then surged by 144.94% to $3.6 million in 2023, then dropped by 25.32% to $2.7 million in 2024, then crashed by 51.09% to $1.3 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $1.3 million, $891000.0, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.